A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

NCT06736327 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: SKB500

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.